Skip to main content

Advertisement

SpringerLink
Log in

Changes of protein expression in prostate cancer having lost its androgen sensitivity

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Objective

The majority of prostate cancers require androgen hormones for growth, and androgen ablation is an important part of the systemic treatment of advanced prostate cancer. Nevertheless, most of these cancers eventually relapse as they become less sensitive to androgen ablation and anti-androgen treatment. Elucidating the molecular events that are responsible for the conversion of androgen-sensitive cancers to androgen-refractory tumors may reveal new therapeutic opportunities.

Methods

In the present study, we investigated nine androgen-sensitive and nine androgen-refractory prostate cancer samples to evaluate the expression levels of 10 selected proteins that have been implicated in oncogenesis and cancer progression.

Results

Our immunohistochemical data show that three of the investigated proteins (i.e., minichromosome maintenance-2, methylguanine-DNA methyltransferase, and androgen receptor) are expressed at significantly different levels in the androgen-refractory cancer samples than in the androgen-sensitive tumors, whereas the expression levels of the seven other studied proteins (i.e., β-catenin, p27, p21, p16, Ki67, hypoxia-inducible factor 1 alpha, and geminin) are not significantly different regarding the two groups.

Conclusions

Our data suggest that the increased expression of minichromosome maintenance-2 and decreased expression of methylguanine-DNA methyltransferase related to androgen receptor are indicative of the androgen-refractory stage in prostate cancer. Further studies are required to determine whether these expression changes play a causative role in the transition of androgen-sensitive to androgen-refractory prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277–300

    Article  PubMed  Google Scholar 

  2. Diokno AC (1998) Epidemiology of prostate cancer. West J Med 169(2):111–112

    CAS  PubMed Central  PubMed  Google Scholar 

  3. Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59(4):572–583

    Article  PubMed  Google Scholar 

  4. Hadaschik BA, Gleave ME (2007) Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol 25:413–419

    Article  CAS  PubMed  Google Scholar 

  5. Williams EM, Higgins JP, Sangoi AR et al (2014) Androgen receptor immunohistochemistry in genitourinary neoplasms. Int Urol Nephrol 47(1):81–85

    Article  PubMed  Google Scholar 

  6. Grossmann ME, Huang H, Tindall DJ (2001) Androgen receptor signaling in androgen- refractory prostate cancer. J Natl Cancer Inst 93:1687–1697

    Article  CAS  PubMed  Google Scholar 

  7. Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23(32):8253–8261

    Article  CAS  PubMed  Google Scholar 

  8. Titus MA, Schell MJ, Lih FB et al (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11(13):4653–4657

    Article  CAS  PubMed  Google Scholar 

  9. Shiota M, Yokomizo A, Naito S (2011) Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. J Mol Endocrinol 47(1):25–41

    Article  Google Scholar 

  10. Vis AN, Noordzij MA, Fitoz K et al (2000) Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol 164(6):2156–2161

    Article  CAS  PubMed  Google Scholar 

  11. Nikoleishvili D, Pertia A, Trsintsadze O et al (2008) Expression of p27((Kip1)), cyclin D3 and Ki67 in BPH, prostate cancer and hormone-treated prostate cancer cells. Int Urol Nephrol 40(4):953–959

    Article  CAS  PubMed  Google Scholar 

  12. Kudahetti SC, Fisher G, Ambroisine L et al (2010) Transatlantic Prostate Group. Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer. Pathology 42(6):519–523

    Article  PubMed  Google Scholar 

  13. Omar EA, Behlouli H, Chevalier S et al (2001) Relationship of p21(WAF-I) protein expression with prognosis in advanced prostate cancer treated by androgen ablation. Prostate 49(3):191–199

    Article  CAS  PubMed  Google Scholar 

  14. Szász AM, Majoros A, Rosen P et al (2013) Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma. Int Urol Nephrol 45(3):727–733

    Article  PubMed Central  PubMed  Google Scholar 

  15. Zhao JH, Luo Y, Jiang YG et al (2011) Knockdown of β-Catenin through shRNA cause a reversal of EMT and metastatic phenotypes induced by HIF-1α. Cancer Investig 29(6):377–382

    Article  CAS  Google Scholar 

  16. Dudderidge TJ, McCracken SR, Loddo M et al (2007) Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer. Br J Cancer 96(9):1384–1393

    CAS  PubMed Central  PubMed  Google Scholar 

  17. Park JY (2010) Promoter hypermethylation in prostate cancer. Cancer Control 17(4):245–255

    PubMed Central  PubMed  Google Scholar 

  18. Williams SG (2006) Characterization of the behavior of tree definitions of prostate specific antigen-based biochemical failure in relation to detection and follow-up biases: comparison with the American Society for Therapeutic Radiology and Oncology consensus definition. Int J Radiat Oncol Biol Phys 64(3):849–855

    Article  CAS  PubMed  Google Scholar 

  19. Hussain M, Goldman B, Tangen C et al (2009) Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from southwest oncology group trials 9346 (intergroup study 0162) and 9916. J Clin Oncol 27(15):2450–2456

    Article  PubMed Central  PubMed  Google Scholar 

  20. Grossmann ME, Huang H, Tindall DJ (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93(22):1687–1697

    Article  CAS  PubMed  Google Scholar 

  21. Jeronimo C, Henrique R, Oliveira J et al (2004) Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer. J Clin Pathol 57(8):872–876

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Jeronimo C, Henrique R, Hoque MO et al (2004) A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 10(24):8472–8478

    Article  CAS  PubMed  Google Scholar 

  23. Kang GH, Lee S, Lee HJ et al (2004) Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 202(2):233–240

    Article  CAS  PubMed  Google Scholar 

  24. Maruyama R, Toyooka S, Toyooka KO et al (2002) Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8(2):514–519

    CAS  PubMed  Google Scholar 

  25. Yamanaka M, Watanabe M, Yamada Y et al (2003) Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 106(3):382–387

    Article  CAS  PubMed  Google Scholar 

  26. Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP, Vadgama JV (2010) Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Molecular cancer therapeutics 9(1):33–45

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1(1):34–45

    Article  CAS  PubMed  Google Scholar 

  28. Melixetian M, Helin K (2004) Geminin: a major DNA replication safeguard in higher eukaryotes. Cell Cycle 3(8):1002–1004

    Article  CAS  PubMed  Google Scholar 

  29. Meng MV, Grossfeld GD, Williams GH et al (2001) Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res 7(9):2712–2718

    CAS  PubMed  Google Scholar 

  30. Romics I, Bánfi G, Székely E et al (2008) Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer. Pathol Oncol Res 14(3):307–311

    Article  PubMed  Google Scholar 

  31. Sugibayashi R, Kiguchi Y, Shimizu T et al (2002) Up-regulation of p21(WAF1/CIP1) levels leads to growth suppression of prostate cancer cell lines. Anticancer Res 22(2A):713–719

    CAS  PubMed  Google Scholar 

  32. Dai Y, Bae K, Siemann DW (2011) Impact of hypoxia on the metastatic potential of human prostate cancer cells. Int J Radiat Oncol Biol Phys 81(2):521–528

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Levente Herényi (Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary) for his continuing support of this research.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, Semmelweis University, Budapest, Hungary

    Gergely Bánfi, Péter Nyirády, Attila Keszthelyi & Imre Romics

  2. 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

    Ivett Teleki, Tibor Krenács & Béla Szende

  3. 2nd Department of Pathology, Semmelweis University, Budapest, Hungary

    Attila Fintha

Authors
  1. Gergely Bánfi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ivett Teleki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Péter Nyirády
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Attila Keszthelyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Imre Romics
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Attila Fintha
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tibor Krenács
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Béla Szende
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gergely Bánfi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bánfi, G., Teleki, I., Nyirády, P. et al. Changes of protein expression in prostate cancer having lost its androgen sensitivity. Int Urol Nephrol 47, 1149–1154 (2015). https://doi.org/10.1007/s11255-015-0985-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-015-0985-1

Keywords

Search

Navigation